Jane Street Group LLC Raises Holdings in The Oncology Institute, Inc. (NASDAQ:TOI)

Jane Street Group LLC increased its stake in shares of The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) by 613.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 127,659 shares of the company's stock after buying an additional 109,769 shares during the period. Jane Street Group LLC owned about 0.17% of Oncology Institute worth $39,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of TOI. Tiff Advisory Services LLC lifted its holdings in Oncology Institute by 13.2% during the 4th quarter. Tiff Advisory Services LLC now owns 2,979,141 shares of the company's stock worth $921,000 after purchasing an additional 346,256 shares in the last quarter. FreeGulliver LLC lifted its position in Oncology Institute by 219.3% in the 4th quarter. FreeGulliver LLC now owns 600,747 shares of the company's stock worth $186,000 after buying an additional 412,578 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Oncology Institute by 7.1% in the 4th quarter. Renaissance Technologies LLC now owns 182,000 shares of the company's stock valued at $56,000 after purchasing an additional 12,000 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Oncology Institute during the fourth quarter valued at about $41,000. Institutional investors own 36.86% of the company's stock.

Oncology Institute Trading Down 6.8%

TOI stock traded down $0.18 during trading on Friday, reaching $2.47. The company had a trading volume of 1,474,767 shares, compared to its average volume of 1,014,829. The Oncology Institute, Inc. has a 52 week low of $0.13 and a 52 week high of $3.50. The business has a 50 day moving average of $2.62 and a 200 day moving average of $1.32. The company has a debt-to-equity ratio of 5.91, a current ratio of 2.49 and a quick ratio of 2.27. The company has a market cap of $220.41 million, a P/E ratio of -3.17 and a beta of 0.13.

Oncology Institute (NASDAQ:TOI - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter. Oncology Institute had a negative return on equity of 186.83% and a negative net margin of 17.63%. The business had revenue of $104.41 million during the quarter.

Analysts Set New Price Targets

Separately, BTIG Research initiated coverage on shares of Oncology Institute in a research report on Thursday, May 15th. They issued a "buy" rating and a $7.00 price objective on the stock.

Insider Transactions at Oncology Institute

In related news, Director Growth I. L.P. M33 sold 673,676 shares of the stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $3.05, for a total transaction of $2,054,711.80. Following the transaction, the director now owns 13,950,557 shares in the company, valued at $42,549,198.85. This represents a 4.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Brad Hively sold 1,976,137 shares of Oncology Institute stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $2.87, for a total transaction of $5,671,513.19. Following the completion of the sale, the director now directly owns 603,501 shares of the company's stock, valued at approximately $1,732,047.87. This trade represents a 76.61% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders purchased 122,258 shares of company stock valued at $127,148 and sold 4,726,137 shares valued at $13,379,013. 8.50% of the stock is owned by insiders.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.